Investor Centre

Pharmaceutical company Pharmaxis (ASX:PXS) has  presented  new analyses from the pooled data of its two large scale phase 3 studies in cystic fibrosis illustrating the longer term benefits for patients who respond to Bronchitol® and the product’s value to healthcare systems. The presentation has been made at this year’s European Cystic Fibrosis Society conference in Lisbon, Portugal where it was awarded “Best Poster”.